Ironwood Pharmaceuticals
Biopharmaceutical company focused on gastrointestinal (GI) diseases. Operates across discovery, clinical development, regulatory compliance and commercialization with emphasis on patient-centered clinical research, quality systems for outsourced manufacturing, and partnerships to advance GI therapies.
Industries
Nr. of Employees
large (251-1000)
Ironwood Pharmaceuticals
Patents
Compositions for colon cleansing and the treatment of gastrointestinal disorders
US-10618938-B2
View Details
Compositions for colon cleansing and the treatment of gastrointestinal disorders
US-10618938-B2
View DetailsProducts
Commercial gastrointestinal therapy (linaclotide)
Commercially marketed gastrointestinal therapy for treatment of certain GI conditions; company reports large-scale patient reach and annual net sales milestones.
Investigational GLP-2 analog (apraglutide) development program
Development program for a once-weekly GLP-2 analog being evaluated for treatment of short bowel syndrome with intestinal failure (SBS-IF).
Commercial gastrointestinal therapy (linaclotide)
Commercially marketed gastrointestinal therapy for treatment of certain GI conditions; company reports large-scale patient reach and annual net sales milestones.
Investigational GLP-2 analog (apraglutide) development program
Development program for a once-weekly GLP-2 analog being evaluated for treatment of short bowel syndrome with intestinal failure (SBS-IF).
Services
Establishes quality agreements, vendor qualification and oversight, and maintains regulatory disposition responsibilities for outsourced GMP activities.
Design and execution of interventional clinical trials, patient engagement, trial registration, real-world evidence collection and biostatistics support.
Commercial planning, field specialty sales operations, and market-facing activities for GI therapies including labeling and distribution oversight.
Management of grant funding, sponsorships, and partnerships with patient and advocacy groups aligned to GI therapeutic focus.
Establishes quality agreements, vendor qualification and oversight, and maintains regulatory disposition responsibilities for outsourced GMP activities.
Design and execution of interventional clinical trials, patient engagement, trial registration, real-world evidence collection and biostatistics support.
Commercial planning, field specialty sales operations, and market-facing activities for GI therapies including labeling and distribution oversight.
Management of grant funding, sponsorships, and partnerships with patient and advocacy groups aligned to GI therapeutic focus.
Expertise Areas
- Clinical trial management
- Gastrointestinal drug development
- CMC and formulation development (small molecules, peptides, proteins)
- Quality systems and GxP compliance
Key Technologies
- Peptide therapeutics (GLP-2 analogs)
- Injectable drug development
- Clinical trial registries and disclosure systems
- Data de-identification / pseudonymization
News & Updates
Regulatory approval granted for use of the company's gastrointestinal therapy in pediatric patients two years of age and older for functional constipation (press release).
Acquisition expanded the pipeline to include an investigational GLP-2 analog being evaluated for once-weekly treatment of short bowel syndrome with intestinal failure.
Regulatory approval granted for use of the company's gastrointestinal therapy in pediatric patients two years of age and older for functional constipation (press release).
Acquisition expanded the pipeline to include an investigational GLP-2 analog being evaluated for once-weekly treatment of short bowel syndrome with intestinal failure.